Testimony on Deactivations for the Capacity Acreditation Reform — Prompt Design (CAR-PD) (with Kevin Coopey). Filed with FERC on 12/30/2025, Attachment D.
Co-lead the design of the Deactivations portion of the proposal.
Cost-Effectiveness Analysis of the Drugs Reimbursed by the Mexican Public Health System for the Second-Line Treatment of PD-L1 Positive, Advanced Non-Small-Cell Lung Cancer (NSCLC) (with C. Baptista). Value in Health, Vol. 20, No. 5, May 2017.
Cost-Effectiveness Analysis of Poractant Alpha (200mg/kg daily) Compared to Beractant (100mg/kg daily), in Premature Infants with Respiratory Distress Syndrome, from the Mexican Institute of Social Security (IMSS) Perspective (with A. Paladio Hernandez, S. Murra-Anton and C. Baptista). Value in Health, Vol. 20, No. 5, May 2017.
Cost-Effectiveness Analysis of Intravitreal Aflibercept Compared with Ranibizumab-PRN in Patients with Wet Age-Related Macular Degeneration (WAMD). Value in Health, Vol. 18, No. 7, November 2015.
Cost-Minimization Analysis of Intravitreal Aflibercept Compared With Ranibizumab On-Label in Patients with Wet Age-Related Macular Degeneration (WAMD). Value in Health, Vol. 18, No. 7, November 2015.